Trial Profile
Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Tumour infiltrating lymphocytes (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms ATATIL
- 11 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Results of an analysis of data as of 02/02/2021 of In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 09 Jul 2020 Planned number of patients changed from 10 to 20.